INTRODUCTION

Defensins comprise a major subclass of the family of antimicrobial peptides. Depending on the size and pairing of their six cysteine residues, defensins of higher vertebrates are classified as α-, β and θ-defensin (Wang et al., 2003). The β-defensins (BD) are characterized by six cysteines and have been found in many animal species such as bovine (Luenser and Ludwig, 2005), ovine (Luenser et al., 2005), porcine and humans (Maxwell et al., 2003). BD is produced principally in the epithelial cells of a number of organs including skin, lung, kidney, pancreas, uterus, eye, and nasal and oral mucosa (Klotman and Chang, 2006). In ovine, β-defensin-1 (sBD-1) is the most prevalent defensin throughout the digestive tract with the exception of the distal ileum (Huttner, 1998).

Defensins are a family of small cationic peptides with a broad range of antimicrobial activities. They can inhibit the growth of fungi, GRAM-positive, and gram-negative bacteria, such as Staphylococcus aureus (Hoover, 2000, 2002), a bacterium that causes infections ranging from skin abscesses to life-threatening conditions such as endocarditis and toxic shock. In recent years, several classes of antimicrobial peptides have been purified from mammalian phagocytes (Sawai, 2002). Similar molecules have also been isolated from specialized epithelia, suggesting that antimicrobial peptides may play a role in the intrinsic resistance of tissues to microbial invasion (Morrison, 2002). sBD-1, as an antimicrobial peptide, can replace the addition of antibiotics to ovine feed. Recently, the antibiotics resistance was hotter and hotter. This would be favorable to consumers because it would eliminate residual antibiotics in meat products. sBD-1 production in vivo shows great promise for veterinary medicine.

Over the past several years, several small cationic peptides have been synthesized successfully by recombinant gene expression methods (Wu et al., 2003). Because of its rapid growth rate and easily established protein expression system, Escherichia coli are used as the host cell (Hans and Kim, 2005). Many difficulties have
been encountered in the expression of genes encoding for antimicrobial polypeptides, often times due to their cytotoxicity and sensitivity to proteolytic degradation (Ganz, 1999, 2004). The fusion strategy (Ma et al., 2009) has been utilized in the production of small antimicrobial cationic peptides in E. coli to alleviate these problems, but fusion proteins tend to form inclusion bodies, which leads to inactivation of the expressed proteins (Li et al., 2004). The E. coli combined translation cell free system is popularly used because of its capability to directly synthesize protein from an exogenous gene. The system can be operated in batch or continuous mode. The batch-mode method is relatively simple and convenient; however, the efficiency of protein synthesis is quite low (Martemyanov et al., 1997; Maxwell et al., 2003).

As a potential therapeutic peptide, the fusion expression of sBD-1 has never been reported. In the present study, both the pre-peptide sBD-1 (psBD-1) and the mature peptide of sBD-1 (msBD-1) were synthesized and expressed using an Escherichia coli expression system. To improve the production of sBD-1, the conditions of cultivation and induction were systematically optimized. The psBD-1 was purified and cleaved to obtain sBD-1 and msBD-1. Antibiotic potencity of the two peptides were observed.

MATERIALS AND METHODS

Strains, plasmids, and culture medium

E. coli DH5αF’ (TaKaRa, Japan) was cultivated at 37°C in LB medium. E. coli BL21 (DE3) was used as the host for the expression of heterologous protein. Plasmid pMD19-T Simple (TaKaRa, Japan) and pET32a (Novagen, USA) were used as cloning and expression vectors, respectively. All restriction enzymes and Tα DNA ligase were purchased from TaKaRa, Japan. Luria–Bertani (LB) medium (w/v) containing 0.5% yeast extract, 1% tryptone and 1% NaCl was used for manipulation of molecular clones and seed cultures.

The cloning of sBD-1

Total RNA of ovine small intestine was isolated using TRIzol reagent (TaKaRa), according to the manufacturer’s recommendations, and then treated with RNase-free DNase I (TaKaRa). The concentration and purity of RNA were checked by absorbance at 260 and 280 nm.

The cDNA fragment encoding the sBD-1 protein was amplified by the reverse transcription polymerase chain reaction (RT-PCR) from total RNA, using ExTag DNA polymerase (TaKaRa), and the synthetic oligonucleotide primers psBD-1 and the mature (msBD-1). DNA amplification was conducted with 35 cycles of denaturation (1 min at 94°C), annealing (1 min at 59°C), and elongation (2 min at 72°C). PCR products were cloned into the PMD19-T simple vector and sequenced by TAKARA company. The cloning plasmid was named PMD19-T-sBD-1. Nucleotide and deduced amino acid sequence comparisons were made using the BLAST (basic local alignment search tool) programs BLASTN (Zhang et al., 2000) and BLASTX, respectively, on non-redundant nucleotide and protein databases of the National Center for Biotechnology Information (http://www.ncbi.nlm.nih.gov/BLAST/). These tools were used to deduce the amino acid sequence encoded by the gene sBD-1.

Construction of expression vectors

The psBD-1 and msBD-1 cDNAs were amplified by PCR, using PMD19-T-sBD-1 as template. Primers are reported in Table 1. PCR products of psBD-1 and msBD-1 cDNAs were purified and cloned between EcoRI and NotI, and Ncol and NotI sites, respectively in pET32a vector. The two cloned vectors were transformed into E. coli BL21 (DE3). The transformed cells were cultured in LB broth at 37°C overnight with shaking at 200 rpm. 500 μl from overnight culture was added into 30 ml of fresh LB containing Amp 0.1 mg/ml for 1 h until the OD reached 0.4 to 0.6. Then the cells were induced by 0.5 mM IPTG. After 5 h incubation, cells were harvested by centrifugation at 12000 rpm for 2 min at 4°C. Cells were then washed by 1×PBS. Subsequently, the first lysis (prolysis) buffer (20 mM sodium phosphate, 0.5 M NaCl, 20 mM imidazole, pH 7.4) was added and mixed to make a homogeneous solution. The cells were lysed by sonication at 30 s pulse on and followed by 10 s pulse off. The cells were centrifuged at 12,000 rpm for 10 min at 4°C. The supernatant was decanted and binding buffer (20 mM sodium phosphate, 0.5 M NaCl, 20 mM imidazole, pH 7.4) was added as the 1 ml HisTrap FF (GE Healthcare, Sweden). The sample was flowed on binding buffer at the rate of 0.5ml/min. After loading the sample, the fusion protein was eluted by elution buffer (20 mM sodium phosphate, 0.5 M NaCl, 500 mM imidazole, pH 7.4). After collection of the protein, the inherent buffer in the sample was exchanged for an enterokinase buffer (50mM Tris pH7.8, 2mM CaCl2, and 50mM NaCl) by gel chromatography using Sephadex G-25. The fusion protein was then digested by the enterokinase (NEB, UK) at room temperature for 24 h. The digested sample was desalted by

<table>
<thead>
<tr>
<th>Parameter</th>
<th>Sequence</th>
</tr>
</thead>
<tbody>
<tr>
<td>psBD-1</td>
<td>5'- CCGGAATTCCAACTAGGGCTCCATCACCTG-3'</td>
</tr>
<tr>
<td></td>
<td>5'- TTTGCGGCGCTTACTTCTTTCTGACGCT-3'</td>
</tr>
<tr>
<td>msBD-1</td>
<td>5'- CTAGCCATGGGTAACTGCTAAGCTGCCAT-3'</td>
</tr>
<tr>
<td></td>
<td>5'- TTTGCGGCGCTTACTTCTTTCTGACGCT-3'</td>
</tr>
<tr>
<td>sBD-1</td>
<td>5'- GAATTCACATGAGGTCACATACCTG-3'</td>
</tr>
<tr>
<td></td>
<td>5'- ATGCAGGCGCTTACTTCTTTCTGACGCT-3'</td>
</tr>
</tbody>
</table>
sBD-1  MRLHLVFLVLSAGGFTQGVRNLSCHRNGCVPSRCPHRQR GTCGPPVKCRKK 64
sBD-2 MRLHLVFLVLSAGGFTQGVRDLSCHRNGCVPSRCPHRQR GTCGPPVKCRKK 64
pBD-1 MRLHLVFLVLSAGGFTQGVRDLSCHRNGCVPSRCPHRQR GTCGPPVKCRKK 64
TAP MRLHLVFLVLSAGGFTQGVRDLSCHRNGCVPSRCPHRQR GTCGPPVKCRKK 64
EBD MRLHLVFLVLSAGGFTQGVRDLSCHRNGCVPSRCPHRQR GTCGPPVKCRKK 64
LAP MRLHLVFLVLSAGGFTQGVRDLSCHRNGCVPSRCPHRQR GTCGPPVKCRKK 64
reBD-1 MRLHLVFLVLSAGGFTQGVRDLSCHRNGCVPSRCPHRQR GTCGPPVKCRKK 64

Figure 1. Comparison of deduced sBD-1 sequences with ovine BD-2, reindeer BD-1 and porcine. Gene Bank numbers are as follow: EBD, AF000362; LAP, S76279; TAP, AF014106; sBD-2, U75251; reBD-1, ABH11654; pBD-1, AF031666.

Antimicrobial assays

Antimicrobial properties of recombinant psBD-1 and msBD-1 were tested against sensitive strains of E. coli 44101 and P. aeruginosa 26003. About 10^5 colony forming units of P. aeruginosa was inoculated into 1 ml M-H medium in the log phase. To deduce the optimal concentration of antimicrobial activity, different concentrations psBD-1 and msBD-1 were tested (pH 7.8, 25 μg/ml). Controls were equivalent volumes of 20 mM Tris buffer. Bacterial cultures were shaken for 14 h and concentrations were determined by measurement of OD_{600}.

The inhibitory zone was measured to determine antimicrobial activity. 400 μl optimal concentrations of psBD-1 or msBD-1 were placed into wells on plated E. coli. The same concentration fusion proteins were also determined. Negative controls used 20 mM Tris buffer.

RESULTS

sBD-1 cloning

Based on RT-PCR, a 214bp sBD-1 cDNA was amplified. sBD-1 encodes a predicted 64 amino acid protein of 7.2 kDa with first 26 amino acid residues serving as a signal peptide. The mature peptide consists of 38 aa residues of about 3.8 KD (Gene Bank number U75250). A BLASTX search of the GenBank protein database showed that the amino acid sequence has homology with other known defensins characterized from different animals with six-conserved cysteine residues forming three disulfide bridges (Figure 1).

Construction of expression vectors and prokaryotic expression of psBD-1 and msBD-1 fusion proteins

The psBD-1 and msBD-1 proteins from prokaryotic expression were purified and characterized. The fusion protein yields were not largely affected by increasing or reducing the concentration of IPTG. Induction time was 6 h at 0.5 mM IPTG; and after 6 h, there was no noticeable change. Molecular weights of psBD-1 and msBD-1 were about 7.2 KDa and 3.8 Kda, respectively. Fusion protein molecular weight of psBD-1 and msBD-1 were 24 KDa and 20 Kda, respectively. The excess peptide was the tag of the pET32 vector. The fusion and purified proteins were loaded into SDS-PAGE to determine the purification effectiveness (Figures 2 and 3).
Cleaving the fusion protein

Fusion proteins were digested by enterokinase; Tricine SDS-PAGE was used to detect cleavage. Digestion products were desalted and freeze-dried (Figure 4).

Antimicrobial assays

psBD-1 did not show antimicrobial activity, even at high concentration (1 mg/ml) (the data was not shown). The optimal concentration of msBD-1 against the P. aeruginosa was shown by percent inhibition (Table 2). The optimal concentration was 96% at 12.5 μg/ml. Moreover, inhibition of E. coli by msBD-1 was demonstrated (Figure 5).

DISCUSSION

The soluble expression of heterologous proteins in E. coli is a good way to obtain the active form of a protein, especially proteins with multiple disulfide bridges. Several expression systems have been developed by fusing an antibiotic peptide with a partner protein or with anionic properties to avoid the toxicity of the heterologous protein to the host cells and the degradation of the products by bacterial proteases (Li et al., 2004; Xiang et al., 2002). msBD-1 is a cationic peptide with three disulfide bridges. The soluble expression of msBD-1 is an optimal method to obtain a bioactive defensin.

Defensins are positively-charged and contain both hydrophobic and hydrophilic domain peptides (Ganz, 2004). They are among the most potent antimicrobial peptides advanced by the mammalian defense system to protect against invading pathogens. The antimicrobial activity is remarkably specific, with little cytotoxicity to mammalian cells even at concentrations ten-fold or higher than those required for antimicrobial activity (Kim et al., 2003). In ovine, sBD-1 is expressed throughout the gastrointestinal tract (Huttner, 1998). This distribution is believed to be very beneficial for protecting the body invaded by microbes. sBD-1 is mainly expressed in the gastrointestinal tract, not in the blood of ovine (Huttner, 1998). sBD-1 is a key element in the bodies first line of defense for ovine.

Bohling et al. (2006) showed that an α-helix is often present at the N-terminus of β-defensins. Because N-terminal regions are often times aliphatic (Karen et al., 2008), this region is likely to direct membrane insertion and disruption. The msBD-1 showed antimicrobial activity while psBD-1 did not. The psBD-1 contains signal peptide, and the N-terminal region is likely to be inactive and not able to insert and disrupt the microbial membrane. The msBD-1 can easily insert and disrupt the microbial membrane because an α-helix is present of the N-terminal.

Defensins are at low concentrations active against bacteria (Kim et al., 2003). Antimicrobial activity of msBD-1 was observed at concentrations as low as 12.5 μg/ml, which strongly inhibited sensitive strains of E. coli. Generally, metabolically active bacteria are much more sensitive to defensins than bacteria made inactive by nutrient deprivation or metabolic inhibitors. Defensins may be the new antimicrobial compounds in the future. This strategy of producing msBD-1 opens a novel way to
produce functional defensins on a large scale and can also become a new method to administer antibiotics in ovine production, especially meat production. In the future, it will be helpful to produce additional defensins for the benefit of veterinary medical research.

Conclusion

In summary, the present study illustrates that msBD-1 can be successfully expressed and purified from E. coli BL21 while retaining their antimicrobial activity. Overall, the proposed approach may have potential benefit for the further designing of defensin-based therapeutic agents.

ACKNOWLEDGEMENT

This work was supported by the National Natural Science Foundation of China (No. 30460093), The People’s Republic of China.

REFERENCES


Table 2. msBD-1 percent inhibition against P. aeruginosa at various concentrations.

<table>
<thead>
<tr>
<th>msBD-1 (μg/ml)</th>
<th>Percent inhibition (%)</th>
</tr>
</thead>
<tbody>
<tr>
<td>50.0</td>
<td>96.3</td>
</tr>
<tr>
<td>25.0</td>
<td>96.1</td>
</tr>
<tr>
<td>12.5</td>
<td>95.9</td>
</tr>
<tr>
<td>6.25</td>
<td>73.3</td>
</tr>
<tr>
<td>3.13</td>
<td>27.8</td>
</tr>
<tr>
<td>1.57</td>
<td>6.4</td>
</tr>
</tbody>
</table>

Figure 5. The bioactivity of msBD-1 against E. coli. Inhibitory zone test, using E. coli. as the sensitive strain: 1. negative control 20-mM Tris (pH 7.8); 2. 10 μg/ml msBD-1; 3. 1 mg/ml msBD-1 fusion protein.


